Bioqual, Inc. (BIOQ)

Market Cap	27.73M -22.5%
Revenue (ttm)	40.24M -14.3%
Net Income	-4.41M
EPS	-4.94
Shares Out	894.42K
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	100
Open	31.00
Previous Close	30.64
Day's Range	31.00 - 31.00
52-Week Range	30.64 - 38.51
Beta	0.01
Analysts	n/a
Price Target	n/a
Est. Earnings	Jan 22, 2027

About Bioqual

Bioqual, Inc. provides in-vivo and in-vitro pre-clinical research services to commercial and government clients in the United States. The company provides contract research services in the areas of AIDS, influenza, respiratory syncytial virus, Coronavirus, malaria, hepatitis, cancer, and other infectious diseases, as well as flavivirus infections, including zika and dengue. It also offers small and large animal models. In addition, the company provides cell-based assays, immunoassay, toxicology and cytotoxicity testing, viral load testing, and ...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1981
• Employees: 113
• Stock Exchange: OTCMKTS
• Ticker Symbol: BIOQ

Financial Performance

In fiscal year 2026, Bioqual's revenue was $39.95 million, a decrease of -18.25% compared to the previous year's $48.87 million. Losses were -$4.17 million, 297.7% more than in 2025.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Nov 11, 2026

Data Sources Report a data error